GlassScriptPhysician profile
Olivia C Ong
NPI 1124021688
$6,997.31
in general payments reported to CMS, 2019-2025
27 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $621 · 2021: $728 · 2022: $1,201 · 2023: $1,219 · 2024: $1,010 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,684.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.62 | 2022-2025 | |
| Sight Sciences, INC. | $910.43 | 2021-2025 | Omni Surgical System |
| Alcon Vision LLC | $910.24 | 2019-2025 | Rocklatan, Clareon, Argos |
| Sun Pharmaceutical Industries INC. | $856.97 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $412.08 | 2019-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $367.02 | 2019-2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $307.25 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Ivantis, INC | $286.75 | 2021 | |
| Allergan, INC. | $261.92 | 2019-2022 | |
| Thea Pharma INC. | $234.75 | 2022-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $228.98 | 2022-2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $191.51 | 2019-2021 | |
| New World Medical,INC. | $162.89 | 2025 | Via360, Streamline, Ahmed Glaucoma Valve |
| Horizon Therapeutics Plc | $118.97 | 2022 | |
| Oyster Point Pharma, INC. | $100.94 | 2023-2025 | Tyrvaya |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.05 | 2019-2021 | |
| Harrow Eye, LLC | $86.01 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $84.77 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $80.71 | 2019-2022 | |
| Shire North American Group INC | $74.32 | 2019 | |
| Dompe US, INC. | $72.19 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $41.81 | 2019 | |
| Merz North America, INC. | $27.67 | 2019 | |
| Rxsight INC | $27.42 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Akorn, INC. | $20.38 | 2019 | |
| Akorn Operating Company LLC | $14.85 | 2021 | |
| Glaukos Corporation | $14.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.